6,6-bis-(4-fluoro-phenyl)-hex-5-enoic acid | 667936-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6,6-bis-(4-fluoro-phenyl)-hex-5-enoic acid
• 英文别名: 6,6-bis(4-fluorophenyl)hex-5-enoic acid
• CAS: 667936-70-1
• 化学式: C₁₈H₁₆F₂O₂
• 分子量: 302.321
• InChiKey: XZFKSXGKGIPNRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6,6-bis-(4-fluoro-phenyl)-hex-5-enoic acid 在 5% Pd(II)/C(eggshell) 、 氢气 作用下， 以 甲醇 为溶剂， 生成 6,6-双(4-氟苯基)-正己酸
  参考文献：
  名称：

  Scaffold-based design and synthesis of potent N-type calcium channel blockers

  摘要：

  The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.008
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 、 4,4'-二氟二苯甲酮 在 lithium hexamethyldisilazane 作用下， 生成 6,6-bis-(4-fluoro-phenyl)-hex-5-enoic acid
  参考文献：
  名称：

  Scaffold-based design and synthesis of potent N-type calcium channel blockers

  摘要：

  The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.008

文献信息

• Calcium channel inhibitors comprising benzhydril spaced from piperazine
  申请人：NeuroMed Technologies, Inc.

  公开号：US20040044004A1

  公开（公告）日：2004-03-04

  Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.

  描述了一些有用于改变钙通道活性的哌嗪取代化合物。
• EP1611116A2
  申请人：——

  公开号：EP1611116A2

  公开（公告）日：2006-01-04
• US6943168B2
  申请人：——

  公开号：US6943168B2

  公开（公告）日：2005-09-13
• [EN] CALCIUM CHANNEL INHIBITORS COMPRISING BENZHYDRIL SPACED FROM PIPERAZINE<br/>[FR] INHIBITEURS DES CANAUX CALCIQUES COMPRENANT DU BENZHYDRYLE ESPACE DE LA PIPERAZINE
  申请人：NEUROMED TECH INC

  公开号：WO2004089922A2

  公开（公告）日：2004-10-21

  Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.